Abstract
Nimotuzumab (TheraCIM, Theraloc, CIMAher, BIOMAb EGFR, YM, CIMYM Biosciences) is an IgG1k humanized monoclonal antibody binding to epithelial growth factor (EGFR), thus inhibiting the tyrosine kinase (TYK) pathways activation. At present, it is approved in over 35 countries,—US, EU, Canada, and Japan not included—for the treatment of adult and pediatric glioma, head and neck carcinoma (HNC), nasopharyngeal carcinoma (NPC), non-small cell lung cancer (NSCLL), cervical and breast cancer, esophageal, colorectal, pancreatic, and prostatic tumors. In 2004, nimotuzumab was designated as orphan drug for the treatment of glioma by FDA and EMEA. However, in 2008 nimotuzumab (under the name of Theraloc) was spontaneously withdrawn from European market for this indication and the same year designated as orphan drug for pancreatic cancer by EMEA, under the name of TheraCIM.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Nimotuzumab (Theracim). YM Biosciences Annual Information Form June 2011
Nimotuzumab (Theraloc) WC500063197 Withdrawal of authorization Dec 2011
Talavera A, Friemann R, Gomez-Puerta S et al (2009) Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res 69:5851–5859
Ramakrishnan MS, Eswaraiah A, Crombet T et al (2009) Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs 1:41–48
Harris RC, Chung E, Coffey RJ (2003) EGF receptor ligands. Exper Cell Res 284:2–13
Boland W, Bebb G (2010) The emerging role of nimotuzumab in the treatment of non-small cell lung cancer. Biol Targ Ther 4:289–298
Ramos-Suzarte M, Lorenzo-Luaces P, Lazo NG et al (2012) Treatment of malignant, non-resectable, epithelial origin esophageal tumors with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy. Cancer Biol Ther 13:600–605
Bode U, Massimino M, Bach F et al (2012) Nimotuzumab treatment of malignant gliomas. Expert Opin Biol Ther 12:1649–1659
Yan S, Jiang I, Yang J et al (2012) Radiotherapy for nasopharyngeal carcinoma and combined capecitabine and nimotuzumab treatment for lung metastases in a liver transplantation recipient: a case experience of sustained complete response. Cancer Biother Radiopharm 27:519–523
Choi HL, Sohn JH, Lee CG et al (2010) A phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results. Lung Cancer 71:55–59
Beckford Vera DR, Eigner S, Eigner Henke C et al (2012) Preparation and preclinical evaluation of 177Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors. Nucl Med Biol 39:3–13
Author information
Authors and Affiliations
Corresponding author
1 Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
Copyright information
© 2014 Springer-Verlag Italia
About this chapter
Cite this chapter
Tridente, G. (2014). Nimotuzumab. In: Adverse Events with Biomedicines. Springer, Milano. https://doi.org/10.1007/978-88-470-5313-7_28
Download citation
DOI: https://doi.org/10.1007/978-88-470-5313-7_28
Published:
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-5312-0
Online ISBN: 978-88-470-5313-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)